Jacobs Levy Equity Management, Inc Relmada Therapeutics, Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $25.8 Billion
- Q4 2024
A detailed history of Jacobs Levy Equity Management, Inc transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 45,602 shares of RLMD stock, worth $12,768. This represents 0.0% of its overall portfolio holdings.
Number of Shares
45,602
Previous 157,672
71.08%
Holding current value
$12,768
Previous $510,000
95.49%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding RLMD
# of Institutions
54Shares Held
8.29MCall Options Held
364KPut Options Held
46.5K-
Franklin Resources Inc San Mateo, CA1.3MShares$364,6020.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.26MShares$351,8770.0% of portfolio
-
Acadian Asset Management LLC Boston, MA1.23MShares$343,8190.0% of portfolio
-
Black Rock Inc. New York, NY573KShares$160,5270.0% of portfolio
-
Palo Alto Investors LP Palo Alto, CA495KShares$138,6400.04% of portfolio
About RELMADA THERAPEUTICS, INC.
- Ticker RLMD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,608,500
- Market Cap $8.01M
- Description
- Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...